MEDICAL CHRONICLE DECEMBER 2018 CPD 3 of 3: Recently the DECLARE trial was published evaluating in a randomised, double-blind, multinational, placebo- controlled trial, the effect of Dapagliflozin on safety and efficacy for macrovascular and microvascular outcomes.

The results of the DECLARE trial indicate that dapagliflozin reduces cardiovascular death and hospitalisation rates for heart failure significantly.

Please sign in to read more